Physician profile
Norbert Delacey
NPI 1861457590
$2,120.12
in general payments reported to CMS, 2019-2025
26 companies · $503 in 2025
The $503 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $31.34 · 2021: $39.51 · 2022: $318 · 2023: $440 · 2024: $655 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.21 | 2019-2024 | Orilissa, Lo Loestrin Fe, Qulipta |
| Astellas Pharma US INC | $265.31 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $223.17 | 2019-2025 | |
| Exeltis, USA INC. | $167.04 | 2019-2025 | Slynd |
| Organon LLC | $156.91 | 2022-2025 | Nexplanon, Jada System |
| Axonics, INC. | $155.99 | 2024 | Axonics, Bulkamid |
| Mayne Pharma Commercial LLC | $136.87 | 2022-2025 | |
| Boston Scientific Corporation | $123.71 | 2025 | Axonics |
| Biogen, INC. | $120.80 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $75.63 | 2022-2023 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Medtronic, INC. | $72.07 | 2022-2024 | Ligasure |
| Davol INC. | $44.72 | 2024 | Arista Ah Flexitip |
| Allergan, INC. | $39.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.43 | 2023-2024 | Recarbrio, Dificid, Zerbaxa |
| Amgen INC. | $32.09 | 2024-2025 | Evenity, Prolia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $30.76 | 2024 | Exparel |
| Sumitomo Pharma America, INC. | $29.42 | 2024-2025 | Myfembree |
| Lsi Solutions INC | $19.29 | 2023 | Fornisee |
| Biohaven Pharmaceutical Holding Company LTD. | $17.60 | 2022 | |
| Karl Storz Endoscopy-America | $17.38 | 2025 | Image1 S Connect |
| Therapeuticsmd, INC. | $15.00 | 2022 | |
| Shield Therapeutics INC | $14.61 | 2024 | |
| Millicent US INC | $14.49 | 2025 | Intrarosa, Femlyv |
| Convatec INC. | $14.31 | 2022 | |
| Smith+Nephew, INC. | $14.02 | 2019 | |
| Pfizer INC. | $13.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norbert Delacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.